Uptake Medical

Uptake Medical® Technology Inc. focuses on developing and commercializing innovative medical devices aimed at improving treatments for pulmonary diseases such as emphysema and lung cancer. Founded in 2004 and headquartered in Tustin, US, Uptake Medical specializes in medical device technology for pulmonary conditions. The company has completed 11 deals, with its most recent funding round being a Venture Debt of USD 1.

92 mn on November 30, 2015, bringing the total amount raised to USD 35. 10 mn. Guowei Zhan serves as the CEO. Uptake Medical® Technology Inc.

specializes in the development and commercialization of innovative medical devices designed to enhance the treatment of pulmonary diseases, particularly emphysema and lung cancer. Their flagship offering, Bronchoscopic Thermal Vapor Ablation® (InterVapor® or BTVA®), utilizes a non-surgical approach to deliver heated vapor to targeted areas of diseased lung tissue. This outpatient procedure is characterized by its minimally invasive nature, requiring typically less than 15 minutes under light sedation, and aims to significantly alleviate breathing difficulties associated with severe emphysema. The primary end users of Uptake Medical's products include patients suffering from chronic pulmonary diseases, while healthcare providers such as hospitals and specialized clinics serve as key clients.

The company's technology is marketed primarily within the United States, focusing on a patient demographic that includes those with severe lung conditions seeking improved quality of life through advanced therapeutic options. Uptake Medical's revenue model is predicated on direct sales to healthcare providers and institutions that offer innovative pulmonary therapies to their patients. The company generates income through the provision of its proprietary vapor ablation technology, specifically the InterVapor® system, which is integrated into the treatment protocols utilized by these healthcare facilities. Transactions typically occur as one-time purchases, wherein hospitals acquire the necessary equipment and consumables for the procedure, ensuring their capacity to deliver advanced treatments to patients.

The structure of these transactions allows for ongoing partnerships with healthcare providers, who may also engage in training and support programs facilitated by Uptake Medical to effectively implement the BTVA procedure. This comprehensive approach not only enhances patient outcomes but also solidifies the company's position within a growing market segment focused on advanced pulmonary care solutions. As of November 2015, Uptake Medical plans to utilize the recently raised USD 1. 92 mn in venture debt funding to support the development of new products aimed at enhancing its therapeutic offerings.

The company is also exploring opportunities to expand its market reach geographically, particularly focusing on international markets to increase its presence in regions with a high prevalence of pulmonary diseases.